The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.

ABSTRACT:

Introduction

Sarcopenia is common in men with metastatic castrate-resistant prostate cancer (mCRPC) and has been largely assessed opportunistically through computed-tomography (CT) scans, excluding measures of muscle function. Therefore, the impact of a comprehensive assessment of sarcopenia on clinical outcomes in men with mCRPC is poorly understood. The objectives of this study were to comprehensively assess sarcopenia through CT scans and measures of muscle function and examine its impact on severe treatment toxicity, time to first emergency room (ER) visit, disease progression, and overall mortality in men initiating chemotherapy or androgen receptor-targeted axis (ARAT) therapy for mCRPC.

Methods

This was a secondary analysis of a prospective observational study of men

SUBMITTER: Papadopoulos E 

PROVIDER: S-EPMC10234556 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature